TECAN and JPT Peptide Technologies announce cooperation agreement
Publication date: 2 October 2012
Author: kdm communications limited
Tagged with: JPT Peptide Technologies GmbH, Siegfried Sasshofer, Tecan
TECAN and JPT Peptide Technologies GmbH, a wholly-owned subsidiary of BIONTECH AG, today announced a collaborative agreement between the two specialist companies. Within the scope of the agreement, the parties agree to co-promote JPT’s wide range of catalog peptide arrays and profiling capabilities alongside TECAN’s portfolio of leading microarray handling devices.
JPT’s peptide microarrays
“We are very glad to have reached an agreement with JPT which presents enormous advantages for both companies, and also for our customers,” stated Siegfried Sasshofer, Director of Marketing Detection at TECAN Austria GmbH. “Providing a high level of data quality and consistency is a burning need in microarray research. JPT is clearly the market leader in the growing field of peptide microarrays and their use for seromarker discovery, immune monitoring and enzyme profiling. Combining JPT peptide microarrays with our Tecan HS 4800™ Pro and HS 400™ Pro hybridization stations for automated microarray processing will provide our customers with a new level of process standardization to maximize the value of their research.”
“Over the past decade Tecan’s instruments have been critical for JPT to develop our PepStar™ peptide array technology into a robust and reliable platform. As a consequence, it is a pleasure to team up with Tecan and to fully reap the benefits of JPT’s peptide arrays with Tecan’s devices for serological and enzymatic assays,” said Holger Wenschuh, CEO of JPT.
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Italy’s pharma market slump: revenue decline to continue, warns GlobalData (21 May 2013)
- Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement (21 May 2013)
- Scientists identify molecular trigger for Alzheimer’s disease (20 May 2013)
- Elan announces transactions: decisively transforming the company (20 May 2013)
- Verona Pharma: ATS Sunday poster presentations (20 May 2013)
Mass Spectrometry: In-depth focus
This free to view Mass Spectrometry in-depth focus features articles from experts at University of British Columbia and University of Colorado Denver.
Stem Cells: In-depth focus
This free to view Stem Cells in-depth focus features articles from experts at Max Planck Institute for Molecular Genetics, Heinrich Heine University and Newcastle University.
Company directory
ABB Analytical Measurements | Analytik Jena AG | Aptalis Pharmaceutical Technologies | ASM - Aerosl-Service AG | Azbil BioVigilant, Inc. | B&W Tek, Inc. | Bio-Optronics, Inc. | bioMérieux | BioTrends – Archilex SA | BMG LABTECH GmbH | Bruker Daltonik GmbH | CAMO Software AS | Catalent Pharma Solutions | Chemical Plant Equipment | Chemspec Europe Ltd | CI Precision | Dow Chemical Company Ltd | DSM Biologics | FOSS NIRSystems, Inc. | GE Analytical Instruments | GenScript USA Inc. | Gerresheimer Group | HACH LANGE GMBH | HAMAMATSU PHOTONICS EUROPE | I Holland Limited | IDBS | IONIMED Analytik GmbH | Lonza | MPI Research | Natoli Engineering Company, Inc. | PANalytical B.V. | Patheon Inc | ReAgent | Roche | Siemens AG | Sirius Analytical Instruments Ltd | TSI | Waters Corporation |
Login to access exclusive content